Proteomics International Laboratories Share Price and Company Fundamentals
Last traded: Today at 4:54 AM
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Key Metrics
PE ratio
-
PB ratio
6.05
Dividend yield
-
Beta
-0.43
Market cap
$80.94M
Enterprise value
$70.80M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.proteomics.com.au |
| Mailing address | QEII Medical Centre QQ Block 6 Verdun Street Nedlands Perth WA 6009 Australia |
| Phone / Fax | 61 8 9389 1992 / |
Dividends
More: Proteomics International Laboratories Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Proteomics International Laboratories paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.PIQ dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Proteomics International Laboratories.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Jacqueline Gray | CFO & Head of Corporate Development | ||
| Mr. John Chuck Morrison | Head of Business Development | ||
| Dr. Scott Bringans | Head of Research | ||
| Dr. Pearl Tan | Head of Product Development | ||
| Dr. Kirsten Peters | Head of Clinical Studies | ||
| Mr. Phillip Prather | Chief Commercial Officer | ||
| Mr. Timothy Luscombe B.Com., C.A. | Company Secretary | ||
| Mr. David Wood | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
-244.98%
Operating margin
-148.28%
Return on assets
-40.28%
Return on equity
-73.41%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Proteomics International Laboratories is 80.94M and its enterprise value is 70.80M. The enterprise value to revenue ratio of PIQ is 21.37. The enterprise value to EBITDA ratio of PIQ is -9.09.
Companies similar to Proteomics International Laboratories (PIQ)
Proteomics International Laboratories (ASX:PIQ) Frequently Asked Questions
1. What is Proteomics International Laboratories's Stock Symbol?
Proteomics International Laboratories trades on ASX under the ticker symbol "PIQ".
2. What is Proteomics International Laboratories's stock price today?
One share of PIQ stock can currently be purchased for approximately $0.49.
3. How can I contact Proteomics International Laboratories?
Proteomics International Laboratories's mailing address is QEII Medical Centre QQ Block 6 Verdun Street Nedlands Perth WA 6009 Australia. The company can be reached via phone at 61 8 9389 1992.
4. What is Proteomics International Laboratories's official website?
The official website of Proteomics International Laboratories is https://www.proteomics.com.au.